Xilio Development Inc Market Cap ($57.12 Million)
Market Cap & Net Worth: Xilio Development Inc (XLO)
Xilio Development Inc market cap. Xilio Development Inc (NASDAQ:XLO) has a market capitalization of $57.12 Million ($57.12 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21173 globally and #4771 in its home market, demonstrating a 18.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xilio Development Inc's stock price $8.68 by its total outstanding shares 6580153 (6.58 Million). Also see how efficiently does Xilio Development Inc generate cash for how efficiently the company converts equity into cash flow.
Xilio Development Inc Market Cap History (2021–2026)
Xilio Development Inc market cap history from 2021 to 2026. Data shows change from $105.28 Million to $57.12 Million (-11.44% CAGR). Check Xilio Development Inc (XLO) stock price for real-time trading data and today's change.
Index Memberships
Xilio Development Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #604 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2013 of 3165 |
Weight: Xilio Development Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Xilio Development Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xilio Development Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Xilio Development Inc equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.10x
Xilio Development Inc's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $6.28 Million | $6.34 Million | -$58.24 Million | 0.99x | N/A |
| 2025 | $4.21 Million | $43.77 Million | -$35.04 Million | 0.10x | N/A |
Competitor Companies of XLO by Market Capitalization
Companies near Xilio Development Inc in the global market cap rankings as of November 4, 2026. Also see XLO total assets for a full breakdown of the balance sheet.
Key companies related to Xilio Development Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Xilio Development Inc (2021–2026)
Market capitalization of Xilio Development Inc from 2021 to today. Between 2021 and today, Xilio Development Inc's market cap moved from $105.28 Million to $ 57.12 Million, with a yearly change of -11.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $57.12 Million | +1255.83% |
| 2025 | $4.21 Million | -32.96% |
| 2024 | $6.28 Million | +73.64% |
| 2023 | $3.62 Million | -79.55% |
| 2022 | $17.70 Million | -83.19% |
| 2021 | $105.28 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Xilio Development Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $57.12 Million USD |
| MoneyControl | $57.12 Million USD |
| MarketWatch | $57.12 Million USD |
| marketcap.company | $57.12 Million USD |
| Reuters | $57.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xilio Development Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumo… Read more